Dr. Sara Lonardi presented promising results from new treatments for metastatic colorectal cancer (mCRC), including cetuximab, amivantamab, and ramucirumab. These treatments have been shown to help control the disease and slow its progression. While survival rates for mCRC are still low, these new options offer hope for patients who have not responded to standard treatments.

The KEYNOTE-811 trial revealed that adding pembrolizumab to standard therapy significantly improves HER2-Positive Metastatic gastric/gastro-oesophageal junction survival rates. This promising approach could shape treatments for this type of cancer and pave the way for future treatment options.

A new study has shown that adding the drugs lenvatinib and pembrolizumab to a common liver cancer treatment called TACE can help people with intermediate-stage hepatocellular carcinoma liver cancer (HCC) live longer without the disease worsening. This combination offers promise, but doctors still need to assess who benefits, mostly due to side effects.

Research suggests that mutations in the KRAS and TP53 genes play a critical role in the development of pancreatic cancer. These mutations are common in cancerous tissues but rare in healthy ones. This discovery could help personalise treatments and improve patient outcomes.

The POD1UM-303 trial showed that adding retifanlimab, an immunotherapy drug, to standard chemotherapy improved survival for patients with metastatic squamous cell carcinoma of the anal canal. This combination may become a new standard treatment.